Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. BAJAJHFL:I
9. CCHGY
10. PRY:IM

Go back to Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson Humphrey

October 16, 2017 11:16 AM EDT

SunTrust Robinson Humphrey raised its price target on Exelixis (NASDAQ: EXEL) to $35.00 (from $33.00) while maintaining a Buy rating.

... More